Is Right-Sided Pleural Mesothelioma Worse than Left-Sided?

Is Right-Sided Pleural Mesothelioma Worse than Left-Sided?

Pleural mesothelioma develops from the thin layer of tissue that covers the lungs and chest wall. Pleural mesothelioma may develop in the lining of the chest wall on just one side of the chest. Previous research has suggested that right-sided pleural mesothelioma is associated with a poorer prognosis. Yet, these were very small studies and estimates were not precise. Dr. Adjepong’s team decided to see if the side mattered. Does it matter if pleural mesothelioma is more on the left or right side? Using National SEER Database to Study Pleural Mesothelioma Malignant pleural mesothelioma is a highly aggressive and rare form of cancer. There are approximately 2,000 cases of mesothelioma diagnosed in the U.S. every year. Mesothelioma is caused by exposure to … Continue reading Is Right-Sided Pleural Mesothelioma Worse than Left-Sided? »

Peritoneal Mesothelioma and Palliative CRS/HIPEC Surgery

Peritoneal Mesothelioma and Palliative CRS/HIPEC Surgery

Peritoneal mesothelioma is the second most common form of asbestos cancer. Peritoneal mesothelioma affects the membrane around the abdominal organs. It can spread throughout the abdomen. Some peritoneal mesothelioma patients get good results with cytoreductive surgery. But success depends on many different factors. Surgical oncologists at the Medical College of Wisconsin are studying this question. Considering Surgery for Palliative Intent? Malignant mesothelioma is an especially aggressive cancer. The two primary types are pleural and peritoneal. Peritoneal mesothelioma used to be considered just as lethal as the more common pleural mesothelioma. But cytoreductive surgery (CRS) and intraperitoneal chemotherapy (HIPEC) have changed that. CRS involves removing as many of the cancer cells as possible. After surgery, the abdomen is cleaned with heated … Continue reading Peritoneal Mesothelioma and Palliative CRS/HIPEC Surgery »

Reviewing Twenty Years of Malignant Mesothelioma in American Women

Malignant Mesothelioma Mortality in American Women

A new study shows twenty years of national trends associated with an increase of mesothelioma deaths in American women. Inhalation of asbestos fibers can cause malignant mesothelioma. Mesothelioma is a rapidly progressing and lethal cancer. It occurs in the mesothelium, a thin layer of tissues surrounding internal organs. It is usually found in the chest and abdomen. Patients with malignant mesothelioma have a poor prognosis. They have an average survival of one year from diagnosis. The estimated average timespan from initial asbestos exposure to death is 32 years. Occupational asbestos exposure is most often reported in men. This is because they often work in industries such as construction and manufacturing. But American women are also at risk for asbestos fiber … Continue reading Reviewing Twenty Years of Malignant Mesothelioma in American Women »

New Advancements in Personalized Medicine for Mesothelioma

New Advancements in Personalized Medicine for Mesothelioma

Genomics is a new branch of medicine that involves using a patient’s genetic information to create personalized treatment. New research has begun looking at genetic personalized medicine for mesothelioma. Students from the University of Montana are developing personalized medicine for mesothelioma. Personalized Medicine and Mesothelioma Treatment Mesothelioma is a rare rare and aggressive cancer often caused by asbestos exposure. Environmental exposure to asbestos often causes a higher incidence of malignant mesothelioma. There are approximately 2,000 cases of mesothelioma diagnosed in the U.S. every year. Current standard of care involves a multi-targeted drug combination of Pemetrexid and Cisplatin. This is the only FDA approved chemotherapy for mesothelioma. Chemotherapy is a group of toxic drugs that kill mesothelioma cells by damaging their … Continue reading New Advancements in Personalized Medicine for Mesothelioma »

Electronic Health Record Supports Malignant Pleural Mesothelioma Research

Electronic Health Record Supports Malignant Pleural Mesothelioma Research

A new method of research is becoming more popular in the study of malignant pleural mesothelioma. Most doctors use an electronic health record (EHR) to track patients and their care. Researchers are now using de-identified data from EHR databases to study mesothelioma. Dr. Wheatley-Price’s team encourages the use of real-word evidence to support treatment choices in malignant pleural mesothelioma. How the Database is Built The electronic health record (EHR) has been in use since the 1960s. Some may call it the electronic medical record (EMR). The large majority of hospitals and clinics now use an EHR system to track patients. There are many different types of EHR systems available. The original purpose of the EHR was to allow a third … Continue reading Electronic Health Record Supports Malignant Pleural Mesothelioma Research »

Second Treatment Course May Increase Mesothelioma Patient Survival

Second Treatment Course May Increase Mesothelioma Patient Survival

Oncologists report that a second treatment course may be a good option for some mesothelioma patients. Almost all mesothelioma patients experience progression after the first treatment. Recommendations for a second treatment are still unclear. There is very limited information available on second and repeat treatments. Pemetrexed combined with platinum-based chemotherapy is a standard first treatment for mesothelioma. A report in BMC Cancer says that a repeat treatment may be good for eligible patients. In this study, patients who received a second treatment of chemotherapy survived longer. Understanding Second Treatments or Retreatments Malignant pleural mesothelioma is a rare, aggressive cancer linked to asbestos exposure. There have been several recent treatment advances. But the mesothelioma prognosis is still poor with an average … Continue reading Second Treatment Course May Increase Mesothelioma Patient Survival »

Nanoparticles May Offer New Treatment for Peritoneal Mesothelioma

Nanoparticles May Offer New Way Treatment for Peritoneal Mesothelioma

American scientists may have found a new way to fight mesothelioma and other cancers from the inside out by targeting cancer cells. A new article published in Biomaterials explores the use of nanoparticles. Peritoneal mesothelioma is an aggressive disease. Patients with peritoneal mesothelioma may survive several or more years after diagnosis. And there are long-term survivors. Peritoneal mesothelioma accounts for 20-25% of all mesothelioma cases. Patients with peritoneal mesothelioma have a longer life expectancy than those with other types of mesothelioma. And some studies report patients live up to 5 years after treatment. Mesothelioma is generally a “chemo-resistant” tumor. Several treatment options are available which include surgery, chemotherapy, and radiation therapy. But traditional chemotherapy often come with toxicities. New Option … Continue reading Nanoparticles May Offer New Treatment for Peritoneal Mesothelioma »

Mesothelioma Patients Underrepresented in European National Cancer Data

Mesothelioma Patients Underrepresented in European National Cancer Data

Cancer patient surveys are important for improving healthcare practice and policy. A new study suggests mesothelioma patients may be underrepresented in this important survey. The goal of the National Cancer Patient Experience Survey is to improve European cancer care. In order to be useful, this survey should represent all cancer patients. Cancer Patient Data Collection using a National Survey Patient feedback from healthcare services is important for informing healthcare quality. And data from patient surveys directly impact policy to improve care. In the United Kingdom, there are many surveys that collect information on patient experiences. For people with cancer, a National Cancer Patient Experience Survey has been taken annually for the last 12 years. It surveys over 65,000 people with … Continue reading Mesothelioma Patients Underrepresented in European National Cancer Data »

New Anti-Mesothelioma Antibody and Biomarker Discovered

New Anti-Mesothelioma Antibody and Biomarker Discovered

Dr. Tsuji is working on discovering specific cancer antigens for malignant mesothelioma. A new study from the Gunma University of Health and Welfare shows a new anti-mesothelioma antibody for the diagnosis and treatment of mesothelioma. The use of antibody drugs is becoming more popular in the treatment of mesothelioma. Antibody drugs are immunotherapy treatments. They recruit your body’s germ-fighting immune system to fight against mesothelioma. One the of biggest problems with mesothelioma immunotherapy is a lack of biomarkers. Mesothelioma is Difficult to Diagnose and Treat with Biomarkers Mesothelioma is a rare and aggressive cancer often caused by asbestos exposure. Malignant mesothelioma is characterized by poor prognosis and short survival. Malignant mesothelioma is considered a treatment-resistant (intractable) cancer. Clinicians and researchers … Continue reading New Anti-Mesothelioma Antibody and Biomarker Discovered »

A Bright Future for Immune Checkpoint Inhibitors in Mesothelioma Treatment

A Bright Future for Immune Checkpoint Inhibitors in Mesothelioma Treatment

A new report shows that immune checkpoint inhibitors can be a practical and rational therapeutic approach to treating mesothelioma patients. The use of ICIs to treat human tumors has quickly become part of clinical practice. Immune checkpoint inhibitors block mesothelioma’s natural resistance to immune system attack. They are among the most promising approaches to combating this intractable cancer. Researchers from the Cellular and Molecular Research Center report the use of ICIs in tumor immunotherapy. What is Tumor Immunotherapy? Malignant mesothelioma is a frustrating disease for patients and doctors. Conventional cancer treatments often do not work. If cancer recurs, doctors can try other approved treatments, even if they are not part of the official treatment guidelines. Immunotherapy is also referred to … Continue reading A Bright Future for Immune Checkpoint Inhibitors in Mesothelioma Treatment »

Get your free copy of
“Surviving Mesothelioma” Today!